Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Nargiza Parpieva"'
Autor:
Shona Horter, Beverley Stringer, Nell Gray, Nargiza Parpieva, Khasan Safaev, Zinaida Tigay, Jatinder Singh, Jay Achar
Publikováno v:
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Introduction Person-centred care, an internationally recognised priority, describes the involvement of people in their care and treatment decisions, and the consideration of their needs and priorities within service delivery. Clarity is requ
Externí odkaz:
https://doaj.org/article/b3f72449525b4864bfde9874275e9b63
Autor:
Anna Engström, Uladzimir Antonenka, Abdylat Kadyrov, Gulmira Kalmambetova, Katharina Kranzer, Matthias Merker, Olim Kabirov, Nargiza Parpieva, Asliddin Rajabov, Evgeni Sahalchyk, Zayniddin Sayfudtinov, Stefan Niemann, Harald Hoffmann
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-5 (2019)
Abstract Background Drug-resistant tuberculosis (TB) is a major public health concern threathing the success of TB control efforts, and this is particularily problematic in Central Asia. Here, we present the first analysis of the population structure
Externí odkaz:
https://doaj.org/article/9ead26140dca40838c81ac81d8eab2c3
Autor:
Philipp du Cros, Atadjan Khamraev, Zinaida Tigay, Tleubergen Abdrasuliev, Jane Greig, Graham Cooke, Krzysztof Herboczek, Tanya Pylypenko, Catherine Berry, Amrita Ronnachit, David Lister, Sebastian Dietrich, Cono Ariti, Khasan Safaev, Bern-Thomas Nyang'wa, Nargiza Parpieva, Mirzagalib Tillashaikhov, Jay Achar
Publikováno v:
ERJ Open Research, Vol 7, Iss 1 (2021)
Background In 2016, World Health Organization guidelines conditionally recommended standardised shorter 9–12-month regimens for multidrug-resistant (MDR) tuberculosis (TB) treatment. We conducted a prospective study of a shorter standardised MDR-TB
Externí odkaz:
https://doaj.org/article/3e70b0468eba4a098cf9018347bf8949
Autor:
Shona Horter, Jay Achar, Nell Gray, Nargiza Parpieva, Zinaida Tigay, Jatinder Singh, Beverley Stringer
Publikováno v:
PLoS ONE, Vol 15, Iss 11, p e0242359 (2020)
IntroductionStandard multidrug-resistant tuberculosis (MDR-TB) treatment is lengthy, toxic, and insufficiently effective. New drugs and a shorter treatment regimen (SCR) are now recommended. However, patient and health-care worker (HCW) perspectives
Externí odkaz:
https://doaj.org/article/2e6e6b9d68344e93991cacea48bed64d
Autor:
Mathieu Bastard, Elisabeth Sanchez-Padilla, Philipp du Cros, Atadjan Karimovich Khamraev, Nargiza Parpieva, Mirzagaleg Tillyashaykov, Armen Hayrapetyan, Kamene Kimenye, Shazina Khurkhumal, Themba Dlamini, Santiago Fadul Perez, Alex Telnov, Cathy Hewison, Francis Varaine, Maryline Bonnet
Publikováno v:
PLoS ONE, Vol 13, Iss 3, p e0193491 (2018)
The emergence of resistance to anti-tuberculosis (DR-TB) drugs and the HIV epidemic represent a serious threat for reducing the global burden of TB. Although data on HIV-negative DR-TB treatment outcomes are well published, few data on DR-TB outcomes
Externí odkaz:
https://doaj.org/article/9fb41413d2e94e538855022f079fa913
Autor:
Jamshid Gadoev, Damin Asadov, Anthony D Harries, Nargiza Parpieva, Katie Tayler-Smith, Petros Isaakidis, Engy Ali, Sven Gudmund Hinderaker, Gozalov Ogtay, Andrew Ramsay, Avazbek Jalolov, Masoud Dara
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0176473 (2017)
BACKGROUND:In Uzbekistan, despite stable and relatively high tuberculosis treatment success rates, relatively high rates of recurrent tuberculosis have recently been reported. Recurrent tuberculosis is when a patient who was treated for pulmonary tub
Externí odkaz:
https://doaj.org/article/ffe8d77f7eae4847b63ef2c33f884512
Autor:
Jamshid Gadoev, Damin Asadov, Mirzagolib Tillashaykhov, Katie Tayler-Smith, Petros Isaakidis, Andrei Dadu, Pierpaolo de Colombani, Sven Gudmund Hinderaker, Nargiza Parpieva, Dilrabo Ulmasova, Avazbek Jalolov, Atadjan Hamraev, Engy Ali, Martin van den Boom, Asmus Hammerich, Ogtay Gozalov, Masoud Dara
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0128907 (2015)
BackgroundTB is one of the main health priorities in Uzbekistan and relatively high rates of unfavorable treatment outcomes have recently been reported. This requires closer analysis to explain the reasons and recommend interventions to improve the s
Externí odkaz:
https://doaj.org/article/2b2e115ea671485b83c2e2c6a13cb195
Autor:
Jay Achar, Catherine Berry, Krzysztof Herboczek, Nargiza Parpieva, Mirzagaleb N. Tillyashaykhov, Zinaida N. Tigay, Atadjan Khamraev, Kalyan Velivela, James A. Seddon, Philipp du Cros
Publikováno v:
Emerging Infectious Diseases, Vol 21, Iss 11, Pp 2105-2106 (2015)
Externí odkaz:
https://doaj.org/article/87a877e88d3440bf90b55884decc0d35
Autor:
Bern-Thomas, Nyang'wa, Catherine, Berry, Emil, Kazounis, Ilaria, Motta, Nargiza, Parpieva, Zinaida, Tigay, Varvara, Solodovnikova, Irina, Liverko, Ronelle, Moodliar, Matthew, Dodd, Nosipho, Ngubane, Mohammed, Rassool, Timothy D, McHugh, Melvin, Spigelman, David A J, Moore, Koert, Ritmeijer, Philipp, du Cros, Katherine, Fielding, Emma, Veitch
Publikováno v:
The New England journal of medicine. 387(25)
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current regimens are needed.We conducted an open-label, phase 2-3, multicenter, random
Autor:
Harald Hoffmann, Bhabana Shrestha, Sara Plesnik, Sabine Hofmann-Thiel, Daniel Czurratis, Martin Eckart, Laura Niebling, Zayniddin Sayfutdinov, Nils Paust, Marina Mihalic, Nargiza Parpieva, Markus Beutler, Vera Allerheiligen, Bhagwan Maharjan, Christoph Metzger-Boddien, Laziz Turaev, Wolfgang Grasse, Ana R. Homann
Publikováno v:
The Journal of Molecular Diagnostics. 23:643-650
Xpert MTB/RIF testing has improved tuberculosis (TB) diagnostics and rifampicin (Rif) resistance testing worldwide. However, it has weaknesses, such as its restriction to Rif resistance testing and the inability to use extracted DNA for further testi